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Abstract
Background: 17alpha-hydroxyprogesterone caproate (17P) administration reportedly improves
outcome for women with a previous spontaneous preterm delivery. This study, using in vitro strips
of human uterine smooth muscle, aimed to investigate the direct non-genomic effects of 17P on
spontaneous and induced contractions in tissues obtained during pregnancy, and in the non-
pregnant state.
Methods: Biopsies of human myometrium were obtained at elective cesarean section, and from
hysterectomy specimens, and dissected strips suspended for isometric recordings. The effects of
17P (1 nmol/L -10 micro mol/L) on spontaneous and agonist-induced (oxytocin 0.5 nmol/L for
pregnant, phenylephrine 10 µmol/L for non-pregnant) contractions were measured. Integrals of
contractile activity, including the mean maximal inhibition values (MMI) observed at the maximal
concentration, were compared with those from simultaneously run control strips.
Results: There was no significant direct effect exerted by 17P on pregnant or non-pregnant human
myometrial contractility. The MMI ± SEM for spontaneous contractions in pregnant myometrium
was 4.9% ± 7.2 (n = 6; P = 0.309) and for oxytocin-induced contractions was 2.2% ± 1.3 (n = 6; P
= 0.128). For non-pregnant myometrium, the MMI ± SEM for spontaneous contractions was 8.8%
± 11.0 (n = 6; P = 0.121) and for phenylephrine induced contractions was -7.9% ± 6.5 (n = 6; P =
0.966).
Conclusions: The putative benefits of 17P for preterm labor prevention are not achieved, even
partially, by a direct utero-relaxant effect. These findings outline the possibility that genomic effects
of 17P, achieved over long periods of administration, are required for its reported therapeutic
benefits.
Background
Preterm delivery constitutes a major problem in obstetric
practice because of the large associated contribution to
perinatal mortality and morbidity [1,2]. A significant pro-
portion of all preterm deliveries are due to spontaneous
preterm labor [2]. Despite much research effort, until
recently, no effective method of preventing or treating pre-
term labor, and improving neonatal outcome, has been
available. Meta-analysis of various tocolytic compounds
in clinical practice has revealed that while they resulted in
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a delay in the interval to delivery, of time periods up to a
week, they did not reduce the incidence of preterm deliv-
ery at different gestational ages [3]. More importantly,
their use, in comparison to placebo, was not associated
with any benefit in terms of objective measures of neona-
tal wellbeing or morbidity.
It has however been recently reported that weekly injec-
tions of 17-alpha-hydroxyprogesterone caproate (17P), in
women who have had a previous spontaneous preterm
delivery, significantly reduces the risk of preterm delivery
before 37, 35 and 32 week's gestation [4]. In addition,
infants of women treated with 17P had significantly lower
rates of necrotising enterocolitis, intraventricular haemor-
rhage and the need for supplemental oxygen. While evi-
dence for the use of progestational compounds for
prevention of preterm delivery, and recurrent miscarriage,
has been conflicting [5-7], meta-analysis restricted to trials
of 17P has suggested a significant reduction in the preterm
delivery rate. This reported benefit of 17P, while being a
welcome development in therapeutic strategies for pre-
term labor, has raised many questions in relation to
whether the same benefit would apply to low risk groups,
and the potential effects, if any, from the castor-oil injec-
tion of placebo used [8,9]. One of the most important
questions relates to the mechanism by which the drug
works and there are currently no data to answer this. Pro-
gestins have the potential to exert both genomic and non-
genomic effects. The aims of this study were focused spe-
cifically on the latter mechanism i.e. to investigate the
direct effects of 17P on contractions of isolated human
myometrium, both spontaneous and agonist-induced, in
tissue obtained during pregnancy and in the non-preg-
nant state.
Methods
Patient Recruitment and Tissue collection
Patient recruitment took place in the Department of
Obstetrics and Gynaecology, University College Hospital
Galway. Ethical committee approval for tissue collection
was obtained from the Research Ethics Committee at Uni-
versity College Hospital Galway and recruitment was by
written informed consent. The biopsies were excised from
the upper lip of the lower uterine segment incision in the
midline i.e. upper portion of lower uterine segment.
Women undergoing induction of labor were excluded
from the study. For hysterectomy specimens, all women
were pre-menopausal and undergoing abdominal hyster-
ectomy without evidence of malignant uterine disease.
Biopsies of myometrial tissue from hysterectomy speci-
mens were obtained from the fundus. The biopsies were
immediately placed in Krebs-Henseleit physiological salt
solution (PSS), pH 7.4, containing: 4.7 mmol/L KCl, 118
mmol/L NaCl, 1.2 mmol/L Mg2SO4, 1.2 mmol/L CaCl2,
1.2 mmol/L KPO4, 25 mmol/L NaHCO3, and 11 mmol/L
glucose. Tissues were stored at 4° C and used within 12
hours of collection.
Tissue Bath Experiments
Longitudinal myometrial strips were dissected measuring
approximately 2 × 2 × 10 mm. The strips were mounted
for isometric recording under 2 grams of tension in organ
tissue baths, as previously described [10-12]. The tissue
baths contained 10 ml of Krebs-Henseleit physiologic salt
solution maintained at 37°C, pH 7.4 and gassed continu-
ously with 95%O2/5%CO2. Myometrial strips were
allowed to equilibrate for at least 60 minutes, during
which time the Krebs-Henseleit physiologic salt solution
was changed every 15 minutes. After the equilibration
period, regular spontaneous myometrial contractions
were allowed to develop. In separate experiments contrac-
tions were induced by the addition of oxytocin (0.5 nmol/
L) to pregnant myometrial strips, and phenylephrine (10
µmol/L) to strips obtained from non-pregnant
myometrium.
Once regular phasic contractions had developed, the inte-
grated tension for the first 20 minutes was calculated, and
this value served as a control since no significant sponta-
neous reduction in myometrial contractility was observed
over the duration of experiments in control strips (with-
out addition of vehicle or 17P). The mechanical response
of tissues was then measured by calculation of the integral
of selected areas for 20 minute periods, corresponding to
the cumulative exposure to 17P or vehicle, using the Pow-
erLab hardware data acquisition system and Chart v3.6
software (AD Instruments, Hastings, UK). At 20 minute
intervals 17P was added in a cumulative manner at con-
centrations of 1 nmol/L, 10 nmol/L, 100 nmol/L, 1 µmol/
L, and 10 µmol/L (i.e., 1 × 10-9 - 1 × 10-5M). Control strips
(i.e. without exposure to 17P) were run simultaneously
and for a similar duration, consisting of two separate
groups of experiments as follows: 1. exposure of strips to
PSS only; 2. exposure of strips to PSS and the vehicle for
17P. The overall duration of experiments was therefore 3
hours which is in accordance with standard in vitro myo-
metrial experiments, allowing for an accurate drug expo-
sure period of 20 minutes. The effects of 17P were assessed
by subtracting the integrals of contractility measured after
each bath exposure of 17P, from those obtained in control
experiments (vehicle only). This allowed for calculation
of the net effect of 17P on myometrial contractility. Poten-
tial effects of the vehicle were obtained by subtraction of
the mean integrals measured after vehicle exposure, from
those obtained without addition of vehicle i.e. spontane-
ous or agonist-induced contractions in PSS only. Percent-
age contractility was calculated by expressing the net
integral measured after each 17P concentration addition,
as a percentage of the integral calculated in the 20 minute
period prior to any 17P addition. The mean maximalReproductive Biology and Endocrinology 2004, 2:80 http://www.rbej.com/content/2/1/80
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inhibition (MMI) refers to the mean percentage relaxation
[i.e. 100% - mean contractility measured for each separate
n sample of non-pregnant and pregnant myometrium]
observed at the maximal bath concentration of 17P (i.e.
10 µmol/L), or corresponding concentration of vehicle for
control strips.
Drugs and Solutions
Oxytocin, phenylephrine and 17P were purchased from
Sigma-Aldrich, Dublin, Ireland. Because 17P is a lipid sol-
uble compound it was necessary to dissolve it in a
lipophilic vehicle. The vehicle used consisted of 75%
Dimethyl sulfoxide (DMSO): 25% ethanol, to make a 1
mmol/L (10-3M) stock solution of 17P. The resultant final
tissue bath concentrations of DMSO and ethanol, at the
maximum concentration of 17P investigated (i.e. 10
µmol/L or 10-5M), were 0.83% and 0.28% respectively,
allowing for the cumulative effect at each bath addition.
DMSO and ethanol were purchased from Sigma-Aldrich,
Dublin, Ireland. Fresh Krebs-Henseleit physiological salt
solution was made daily. Fresh 17P solutions were pre-
pared on the day of experimentation and were maintained
at room temperature for the duration of the experiment.
Statistical Analysis
The integrals of contractile activity measured were com-
pared to control values, and expressed as a percentage of
that measured before drug addition. The effects of 17P on
myometrial contractility were calculated for each 20-
minute period of exposure from 1 nmol/L-10 µmol/L, and
compared with the measurements obtained from control
strips (ie. spontaneous, oxytocin-induced or phenyle-
phrine-induced contractility, in the presence and absence
of vehicle). The integrals of contractile activity were com-
pared using a one-way ANOVA, which was followed by a
Tukey HSD post-hoc. A value of P < 0.05 was accepted as
statistical significance.
Results
There were 6 women recruited for the study at the time of
elective cesarean section. The reasons for cesarean section
included previous cesarean section (n = 2), breech presen-
tation (n = 2), unstable lie (n = 1) and postmaturity with
poor cervical Bishop score (n = 1). The mean age, ± stand-
ard error of the mean (SEM), was 36.3 ± 2.8 years (range
26–46). The median gestation at the time of cesarean sec-
tion was 39 weeks (range 38–41). In relation to parity, 2
of the women were para 0, 1 was para 1, and 3 were of par-
ity greater than 1, at the time of recruitment. There were 6
women recruited at the time of abdominal hysterectomy.
The reasons for hysterectomy included menorrhagia (n =
4), irregular vaginal bleeding (n = 1), and fibroids with an
ovarian cyst (n = 1). The mean age ± SEM was 42.2 ± 2.4
years (range 36–50).
For non-pregnant myometrial tissue representative
recordings are shown in Figure 1. In Figure 1A a recording
of spontaneous myometrial contractions is shown. In Fig-
ure 1B, the effects of vehicle for 17P on spontaneous con-
tractions is demonstrated, and in Figure 1C the effects of
addition of 17P are shown. The results of the calculated
integrals are provided in Table 1. Bath exposure of the
strips from hysterectomy specimens to 17P did not result
in any alteration in contractile activity, at any of the bath
concentrations studied, in comparison to vehicle only
experiments (spontaneous contractions: P = 0.121; phe-
nylephrine-induced contractions: P = 0.966).
The results obtained from myometrium during pregnancy
are similarly shown in Figure 2, and in Table 1. Figures 2A,
2B and 2C demonstrate recordings of oxytocin-induced
contractions, the effects of vehicle, and the effects of 17P
respectively. There was no significant net relaxant or uter-
otonic effect exerted by 17P on pregnant myometrial con-
tractility, at any of the bath concentrations studied
experiments (spontaneous contractions P = 0.309; oxy-
tocin-induced contractions: P = 0.128). No significant dif-
ference was observed between the effects of 17P on
contractility in either pregnant or non-pregnant
myometrium.
Table 1: Mean Maximal Inhibition Values for Vehicle and 17P.
Myometrial Contractility Non-Pregnant Pregnant
Net Vehicle Relaxation ± 
SEM
Net 17P Relaxation ± SEM Net Vehicle Relaxation ± 
SEM
Net 17P Relaxation ± SEM
Spontaneous -0.6% ± 12.1 (n = 6) 8.8% ± 11.0 (n = 6) 49.7% ± 11.9 (n = 6)♦ 4.9% ± 7.2 (n = 6)
*Agonist-Induced 31.8% ± 5.0 (n = 6) -7.9% ± 6.5 (n = 6) 56.2% ± 2.3 (n = 6)¶ 2.2% ± 1.3 (n = 6)
*Phenylephrine-induced in non-pregnant myometrium and oxytocin-induced in pregnant myometrium.
♦ P = 0.022 in comparison to controls with PSS only
¶ P < 0.001 in comparison to controls with PSS onlyReproductive Biology and Endocrinology 2004, 2:80 http://www.rbej.com/content/2/1/80
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The vehicle for 17P independently exerted a uterorelaxant
effect on spontaneous and agonist-induced contractions
in pregnant myometrial tissue only (spontaneous contrac-
tions P = 0.022; oxytocin-induced contractions: P =
0.000), and this was not observed in non-pregnant myo-
metrial tissue (spontaneous contractions P = 0.241; phe-
nylephrine-induced contractions: P = 0.068) (Table 1).
Discussion
These results demonstrate that 17P does not appear to
exert a direct relaxant effect on human myometrial con-
tractions in vitro, in tissue obtained during the third tri-
mester of pregnancy, or in the non-pregnant state. These
findings are in contrast to the inhibitory effect of proges-
terone derivatives on spontaneous contractions in animal
uterine tissues [13,14], and therefore suggest that the
reported benefit of 17P in preventing preterm delivery in
women who have had a previous preterm delivery,
involves other mechanisms of action, presumably via its
genomic effects. It seems likely that prolonged exposure of
uterine smooth muscle to 17P, with resultant activation of
the progesterone receptor isoforms, has the potential to
modify gene transcription in order to maintain physiolog-
ical uterine quiescence. However no direct effect on con-
tractile activity was observed in our study over a period of
hours of exposure.
Previous studies, using various progestins, have yielded
conflicting results in terms of the direct effects of these
metabolites on human myometrial contractility in vitro.
Progesterone metabolites, in some studies, have been
reported to decrease both the frequency and amplitude of
contractions [15-17], while other reports have outlined
Effects of 17P on myometrial contractility in non-pregnant  tissue Figure 1
Effects of 17P on myometrial contractility in non-pregnant 
tissue. Representative recordings of spontaneous contrac-
tions in PSS only (A), the effects of cumulative additions of 
17P vehicle (B), and the effects of cumulative additions of 17P 
(C) are shown.
Effects of 17P on myometrial contractility in pregnant tissue Figure 2
Effects of 17P on myometrial contractility in pregnant tissue. 
Representative recordings of oxytocin-induced contractions 
in PSS only (A), the effects of cumulative additions of 17P 
vehicle (B), and the effects of cumulative additions of 17P (C) 
are shown.Reproductive Biology and Endocrinology 2004, 2:80 http://www.rbej.com/content/2/1/80
Page 5 of 6
(page number not for citation purposes)
that progesterone stimulates the frequency and tonus of
contractions in term human myometrium [18,19]. It has
been hypothesized that progesterone addition to myome-
trial strips only enhances contractility if the tissue speci-
men was never deprived of progesterone i.e. placed
immediately in a medium containing progesterone [19].
The studies to date have included various progesterone
metabolites but we are unaware of any previous studies
evaluating the effects of 17P on human myometrial con-
tractions in vitro. The focus on 17P in this study has arisen
from the recently reported randomized clinical trial out-
lining its benefits clinically for recurrent preterm labor.
17P is a naturally occurring progesterone which has been
isolated from corpus luteum and adrenal gland. The syn-
thetic caproate ester, like the naturally occurring com-
pound, is a steroid, is highly lipophilic and is inactive
when administered orally. To achieve solubility for clini-
cal studies, the vehicle used for injection was castor-oil
[4]. This led to significant controversy in relation to the
potential effect of castor-oil on myometrial contractions
in the placebo arm of the recently reported study [8]. For
laboratory, or in vitro studies, achieving the required sol-
ubility of progestins can also be a difficult process. Efforts
to achieve solubility in previous reports have included the
use of Hepes buffer and ultrasound baths [19,20] with a
resultant maximum 50% solubility. After numerous
attempts at solubility for 17P in our studies, the most
appropriate vehicle was a combination of DMSO and eth-
anol. While both of these compounds may exert an effect
on uterine contractility, the maximal bath concentrations
of both solvents was 0.83% and 0.28% respectively,
which is acceptable for in vitro studies of this nature. In
addition, control experiments, with PSS only, and PSS
plus vehicle, were simultaneously run, to clearly evaluate
any potential effect of vehicle. It is however apparent from
our results, that addition of vehicle only did exert a
significant relaxant effect on myometrium obtained dur-
ing pregnancy, but no effect of vehicle was observed in
myometrium obtained in the non-pregnant state. For
both tissues, addition of 17P did not alter contractile
activity. While the vehicle effects observed were sizeable,
the experiment design, the numbers of patients recruited,
and the reproducibility of the results, clearly indicate that
17P does not exert a direct effect on human myometrial
contractility. In addition, while the experiments described
here investigated the effects of 17P added cumulatively,
separate experiments (data not shown) using a single dose
(the highest dose) revealed similar results i.e. there was no
evidence of tachyphylaxis over the duration of the
experiments.
There are some limitations to the methodology used in
our study. The tissue biopsies from the non-pregnant
uterus were obtained from the body of the uterus, while
those obtained at the time of caesarean section were
excised from the lower uterine segment. The results were
similar for both tissue types, and there is reasonable evi-
dence to suggest that the functional characteristics of
lower and upper uterine segment myometrium are similar
[21]. At present there are no data pertaining to differential
progesterone receptor expression levels between upper
and lower uterine segments. There are also obvious ethical
constraints in obtaining biopsies from the upper segment
of the uterus at cesarean section, and it is not feasible to
dissect strips with certainty from the lower segment of the
non-pregnant uterus. Secondly, the tissue samples
obtained during pregnancy were all recruited from
women at term. It could be that preterm myometrium dis-
plays a different responsiveness. Finally, in vivo adminis-
tration of 17P could potentially result in the formation of
a metabolite with a more efficient uterorelaxant effect.
Conclusions
Whether 17P injections become incorporated for routine
use in the management of preterm labor remains to be
seen. Questions surrounding its true benefits, the associ-
ated difficulties in terms of vehicle solubility and placebo,
and the mechanism of action, remain. Our findings high-
light the solubility problems for scientific evaluation as
occurred in clinical studies. Whatever the possible mecha-
nism of action of 17P in reducing the incidence and
adverse sequelae of preterm labor, this study demon-
strates that it does not exert a direct relaxant effect, unlike
other conventional methods of tocolysis investigated, and
raised the likeliehood of a genomic effect secondary to
long term administration during pregnancy.
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